120 related articles for article (PubMed ID: 4895445)
1. [Urokinase "Green Cross", a new urokinase preparation. II. In vivo studies].
Fischer M; Pilgerstorfer HW
Int Z Klin Pharmakol Ther Toxikol; 1969 Apr; 2(2):142-9. PubMed ID: 4895445
[No Abstract] [Full Text] [Related]
2. [Thrombolytic therapy. I. Introduction and principles of therapy. Indications. Contraindications. Schematics of the treatment].
Sterkowicz S
Przegl Lek; 1969; 25(8):565-8. PubMed ID: 4897431
[No Abstract] [Full Text] [Related]
3. Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study.
Gormsen J; Tidstrom B; Feddersen C; Ploug J
Acta Med Scand; 1973; 194(3):191-8. PubMed ID: 4583532
[No Abstract] [Full Text] [Related]
4. Fibrinolytic enhancement by stanozolol: a double blind trial.
Davidson JF; Lochhead M; McDonald GA; McNicol GP
Br J Haematol; 1972 May; 22(5):543-59. PubMed ID: 4555715
[No Abstract] [Full Text] [Related]
5. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
Marder VJ; Francis CW
Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
[No Abstract] [Full Text] [Related]
6. [Systemic effects of thrombolytic therapy].
Balduini CL; Gamba G; Bertolino G; Noris P; Previtali M; Ascari E
Haematologica; 1991 Jun; 76 Suppl 3():281-90. PubMed ID: 1752524
[No Abstract] [Full Text] [Related]
7. [Pharmacologic principles of fibrinolytic therapy].
Markwardt F
Z Gesamte Inn Med; 1987 Sep; 42(17):473-8. PubMed ID: 3318182
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
9. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
10. In vivo role of factor XII (Hageman factor) in hypercoagulability and fibrinolysis.
Herold R; Straub PW
J Lab Clin Med; 1972 Mar; 79(3):397-412. PubMed ID: 5061394
[No Abstract] [Full Text] [Related]
11. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
Páramo JA; Collen D
Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
[No Abstract] [Full Text] [Related]
12. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
13. [Thrombolytic therapy].
Schmutzler R; Koller F
Ergeb Inn Med Kinderheilkd; 1965; 22():157-210. PubMed ID: 5889464
[No Abstract] [Full Text] [Related]
14. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.
Ludlam CA; Bennett B; Fox KA; Lowe GD; Reid AW
Blood Coagul Fibrinolysis; 1995 May; 6(3):273-85. PubMed ID: 7654941
[No Abstract] [Full Text] [Related]
15. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
16. [Studies on blood coagulation and fibrinolytic activities in the three cases of cerebral infarction treated with urokinase. 1st report--120,000 I.U. administrated-- (author's transl)].
Fujita S; Itoga T; Shou T; Yamamoto H; Ishikawa H
Rinsho Ketsueki; 1978 Jun; 19(6):850-8. PubMed ID: 713046
[No Abstract] [Full Text] [Related]
17. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers.
Prowse CV; Hornsey V; Ruckley CV; Boulton FE
Thromb Haemost; 1982 Apr; 47(2):132-5. PubMed ID: 7048621
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosis.
Marder VJ
Circulation; 1983 Aug; 68(2 Pt 2):I2-5. PubMed ID: 6683134
[TBL] [Abstract][Full Text] [Related]
19. [Study on the influence of vasculo-tissular factors on coagulation and fibrinolysis. X. Release of anticoagulants and plasminogen activators after induced venous stasis and behavior of the coagulative-fibrinolytic system in subjects with recent myocardial infarct].
Neri Serneri GG; Rossi Ferrini PL; Paoletti P; Silvestrini E; Masotti G
Mal Cardiovasc; 1966; 7(2):237-56. PubMed ID: 5335302
[No Abstract] [Full Text] [Related]
20. [Characteristics of the fibrinolytic system in the newborn].
Schlegel N; Hurtaud-Roux MF; Beaufils F
Ann Pediatr (Paris); 1993 Feb; 40(2):70-4. PubMed ID: 8457135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
